Zeus Sleep has secured a £150,000 investment from British Design Fund to help accelerate the development of its groundbreaking solutions designed to alleviate the symptoms of snoring and sleep apnoea.
The UK-based startup is on a mission to improve the sleep quality of one million people over the next decade. Its cutting-edge, non-invasive devices aim to address the root causes of disruptive sleep, offering relief to individuals struggling with snoring and sleep apnoea, as well as improving wellbeing for their partners and families.
Chronic snoring is thought to affect nearly a quarter of adults and can lead to health issues, fatigue, and strained relationships. Traditional treatments for sleep disorders can be intrusive, uncomfortable, and costly. Zeus’ innovative solutions provide a clinically tested, discreet, and affordable alternative, ensuring restful nights and revitalised daily energy levels.
Founded by experts in medical technology and engineering, Zeus Sleep has worked closely with Guy’s & St Thomas’ Hospital, King’s College London, and Morgan Innovation & Technology Ltd – an award-winning B Corp with a track record in healthcare innovation. More than a decade of research has gone into the development of Zeus’ devices, which have undergone three clinical trials validating their effectiveness.
The investment will support Zeus Sleep’s expansion, with the company planning to launch its first consumer product targeting snoring soon, with pre-orders now being taken. A medical-grade device aimed at alleviating mild to moderate obstructive sleep apnoea is set to follow in 2026.
In March 2025, Zeus Sleep announced the successful completion of its first fundraising round, exceeding its target by an impressive 40%.
